Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non–Small-Cell Lung Cancer

Lau, Steven; Gannavarapu, Bhavani S.; Carter, Kristen; Gao, Ang; Ahn, Chul; Meyer, Jeffrey; Sher, David J.; Jatoi, Aminah; Infante, Rodney E.; Iyengar, Puneeth

doi:10.1200/jop.2017.025239

Cited by 20 publications

(14 citation statements)

References 15 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have used body weight and BMI as indicators of general condition in patients receiving chemotherapy (Castillo-Martínez et al, 2018). Furthermore, pretreatment weight loss is a poor prognostic factor in lung cancer patients (Lau et al, 2018). In recent years, the concepts of cachexia, sarcopenia, and frailty have become widespread, and studies based on these concepts have been conducted in the area of cancer treatment (Jain, Coss, Whooley, & Phelps, 2020;Kidd, Skrzypski, Jamal-Hanjani, & Blyth, 2019;Kurishima, Watanabe, Ishikawa, Satoh, & Hizawa, 2017;Nakamura et al, 2018;Phillips, Hug, Allan, & Ezhil, 2019).…”

Section: Discussionmentioning

confidence: 99%

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Kayauchi

Nakagawa

Oteki

et al. 2020

Asian Pac Isl Nurs Js

View full text Add to dashboard Cite

Although advances have been made in the treatment and prevention of febrile neutropenia (FN) in cancer patients treated with chemotherapy, it is still a complication that requires clinical attention. Impaired nutritional status in patients who develop FN can affect the continuation of cancer treatment, but it has not been investigated. We conducted a retrospective longitudinal study in order to clarify (1) if body weight and serum albumin levels change in lung cancer patients who do and do not develop FN, and (2) if these indicators are more likely to worsen in patients with FN than in patients without FN. Patients undergoing cytotoxic chemotherapy between January 2011 and June 2020 were consecutively included in the study. Changes in body weight and serum albumin levels were investigated in a case–control study of patients with FN, and control patients without FN who were matched by age, gender, histopathology, and stage of lung cancer, at a ratio of 1:2. During the study period, 226 patients received cytotoxic chemotherapy. Among those, 33 (14.6%) patients developed FN during the first course of cytotoxic chemotherapy. We found a more pronounced decrease in both body weight and serum albumin level at four weeks after the initiation of chemotherapy in FN patients. In order to safely administer effective chemotherapy, medical staff need to pay close attention to the nutritional status of patients receiving chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Kayauchi

Nakagawa

Oteki

et al. 2020

Asian Pac Isl Nurs Js

View full text Add to dashboard Cite

show abstract

“…1 Even when cachexia is identified in early stage cancer patients, survival is not improved because of a potential lack of effective therapeutic interventions. 2 Although cachexia has been recognized for more than half a century, most preclinical studies and clinical trials targeting the immune system [tumour necrosis factor alpha (TNF-α) and interleukin (IL)-6], appetite stimulation, and muscle regeneration have failed to durably improve the syndrome. 3 The majority of studies on cachexia have focused on the sarcopenia of this wasting syndrome, with less emphasis on adipose loss or anorexia.…”

Section: Introductionmentioning

confidence: 99%

Janus kinase inhibitors suppress cancer cachexia‐associated anorexia and adipose wasting in mice

Arora

Gupta

Guo

et al. 2020

JCSM Rapid Communications

Self Cite

View full text Add to dashboard Cite

Background Cachexia, a syndrome of muscle atrophy, adipose loss, and anorexia, is associated with reduced survival in cancer patients. The colon adenocarcinoma C26c20 cell line secretes the cytokine leukaemia inhibitory factor (LIF), which induces cachexia. We characterized how LIF promotes cachexia-associated weight loss and anorexia in mice through Janus kinase (JAK)dependent changes in adipose and hypothalamic tissues. Methods Cachexia was induced in vivo with the heterotopic allotransplanted administration of C26c20 colon adenocarcinoma cells or the intraperitoneal administration of recombinant LIF in the absence or presence of JAK inhibitors. Blood, adipose, and hypothalamic tissues were collected and processed for cytokine/adipokine enzyme-linked immunosorbent assays, immunoblot analysis, and quantitative reverse transcription polymerase chain reaction (RT-PCR). Cachexia-associated lipolysis was induced in vitro by stimulating differentiated adipocytes with recombinant LIF or interleukin (IL)-6 in the absence or presence of lipase or JAK inhibitors. These adipocytes were processed for glycerol release into the media, immunoblot analysis, and RT-PCR. Results Tumour-secreted LIF induced changes in adipose tissue expression and serum levels of IL-6 and leptin in a JAK-dependent manner influencing cachexia-associated adipose wasting and anorexia. We identified two JAK inhibitors that block IL-6 family-mediated adipocyte lipolysis and IL-6 induction using an in vitro cachexia lipolysis assay. JAK inhibitors administered to the in vivo C26c20 cancer cachexia mouse models led to (i) a decrease in signal transducer and activator of transcription 3 phosphorylation in hypothalamic and adipose tissues, (ii) a reverse in the cachexia serum cytokine/adipokine signature, (iii) a delay in cancer cachexia-associated anorexia and adipose loss, and (iv) an improvement in overall survival. Conclusions JAK inhibitors suppress LIF-associated adipose loss and anorexia in both in vitro and in vivo models of cancer cachexia.

show abstract

“…1 Even when CX is identified in early stage cancer patients, survival is not improved because of a potential lack of effective therapeutic interventions. 2 Although CX has been recognized for more than half a century, most preclinical studies and clinical trials targeting the immune system (TNF-α, IL-6), appetite stimulation, and muscle regeneration have failed to durably improve the syndrome. 3 The majority of studies on CX have focused on the sarcopenia of this wasting syndrome, with less emphasis on adipose loss or anorexia.…”

Section: Introductionmentioning

confidence: 99%

JAK Inhibitors Suppress Colon Cancer Cachexia-Associated Anorexia and Adipose Wasting in Mice

Arora

Gupta

Guo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Abbreviations: CX, cachexia; IL-6, interleukin 6; JAK, janus kinase; LIF, leukemia inhibitory factor; rLIF, recombinant leukemia inhibitory factor; STAT3, signal transducer and activator of transcription 3. ABSTRACTBackground: Cachexia (CX), a syndrome of muscle atrophy, adipose loss, and anorexia, is associated with reduced survival in cancer patients. The colon adenocarcinoma C26c20 cell line secretes the cytokine leukemia inhibitor factor (LIF) which induces CX. We characterized how LIF promotes CX-associated weight loss and anorexia in mice through JAK-dependent changes in adipose and hypothalamic tissues.Methods: CX was induced in vivo with C26c20 colon adenocarcinoma cells or recombinant LIF administration in the absence or presence of JAK inhibitors. Blood, adipose, and hypothalamic tissues were collected and processed for cyto/adipokine ELISAs, immunoblot analysis, and quantitative RT-PCR. CX was induced in vitro by stimulating differentiated adipocytes with recombinant LIF or IL-6 in the absence or presence of lipase or JAK inhibitors. These activated adipocytes were processed for lipolysis, immunoblot analysis, and RT-PCR.Results: Tumor-secreted LIF induced changes in adipose tissue expression and serum levels of IL-6 and leptin in a JAK-dependent manner influencing CX-associated adipose wasting and anorexia. We identified two JAK inhibitors that block cytokine-mediated adipocyte lipolysis and IL-6 induction using an in vitro CX lipolysis assay. JAK inhibitors administered to in vivo colon cancer CX mouse models led to 1) a decrease in STAT3 phosphorylation in hypothalamic and adipose tissues, 2) a reverse in the CX serum cyto/adipokine signature, 3) a delay in colon cancer CX-associated anorexia and adipose loss, and 4) an improvement in overall survival. Conclusions: JAK inhibitors suppress cytokine-associated adipose loss and anorexia in multiple in vitroand in vivo models of cancer CX.

show abstract

Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non–Small-Cell Lung Cancer

Cited by 20 publications

References 15 publications

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

Janus kinase inhibitors suppress cancer cachexia‐associated anorexia and adipose wasting in mice

JAK Inhibitors Suppress Colon Cancer Cachexia-Associated Anorexia and Adipose Wasting in Mice

Contact Info

Product

Resources

About